Resources and Tools

Take advantage of the wide variety of resources that CSL Behring offers. Order educational materials about von Willebrand disease (VWD), access an award-winning website on VWD, or register for e-mail updates — and receive a book about VWD, with our compliments.

Patient Assistance Program

This program provides medically necessary therapies to qualified patients who are uninsured, underinsured, or who cannot afford their prescribed therapy.

AllAboutBleeding-US.com

Access a Web site dedicated to increasing awareness about Bleeding Disorders, von Willebrand Disease (VWD), Hemophilia and other rare bleeding disorders.

Mix2Vial™

Mix2Vial™ is a plastic, needle-free transfer device for use with Humate-P. For healthcare providers, patients, and parents, the Mix2Vial™ is efficient and convenient, helping to minimize the risk of accidental injury and the time required to prepare Humate-P.

Events

To stay informed about the latest news in bleeding disorders, you may be interested in attending the conferences and meetings listed below.* CSL Behring will be participating in all of these events, so please stop by our exhibit booth and get information on Humate-P, speak with a CSL Behring representative, or obtain brochures.

National Hemophilia Foundation
Annual Meeting
November 11-13, 2010
New Orleans, LA
www.hemophilia.org

*Upcoming conference dates will be posted when they become available.

Most local hemophilia chapters have a Web site, which typically includes a calendar of events. To find a chapter near you, visit the National Hemophilia Foundation Web site.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.